this article describes the acelrx's fiyrtg quarter and Tetraphase acquisition conference call. the acelrx's co-promotion agreement is a strategic strategic alignment for the acelrx and xava pharmaceuticals. the acquisition is consistent with the plan to expand and diversify the company's product portfolio and better leverage its expertise and infrastructure. it further builds on management's plan and strategy to create a growth platform towards becoming a leader and providing innovative treatments to healthcare institutions.